Blood marker may forecast deadly pancreatic surgery complications

NCT ID NCT07144917

Recruiting now Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Apr 16, 2026 · Last updated Jun 09, 2026 · Updated 10 times

Summary

This study looks at whether a blood marker called mHLA-DR can help doctors predict severe complications after pancreatic surgery. About 100 people having this surgery will be followed. The goal is to find an early warning sign for problems like infection or pancreatic leaks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Aurélien DUPRE
NOT_YET_RECRUITING

Lyon, 69008, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Jean-Christophe LIFANTE
NOT_YET_RECRUITING

Pierre-Bénite, 69495, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Julie PERINEL
NOT_YET_RECRUITING

Lyon, 69003, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Xavier MULLER
RECRUITING

Lyon, 69004, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) PANCREATIC FISTULA PANCREATIC HEAD TUMOUR